VIVUS, Inc. (NASDAQ:VVUS)

About the company

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

59

CEO

John P. Amos

Exchange

NASDAQ

Website

http://www.vivus.com

$73.00M

Total Revenue

59

Employees

$8.88M

Market Capitalization

-0.30

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$57M

Operating Margin (in %)

Total operating margin

$-9M

Net Margin (in %)

Total net margin

$-29M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12030.90 1376.00 5.13 18.97 43.06
Catalent, Inc. CTLT 10896.37 2872.00 5.47 104.47 3.63
Perrigo Co. Plc PRGO 7562.40 4837.00 1.30 51.59 3.02
Bausch Health Cos., Inc. BHC 6505.79 8597.00 9.08 -3.44 -21.96
Jazz Pharmaceuticals Plc JAZZ 6200.46 2188.00 2.14 22.66 12.81
United Therapeutics Corp. UTHR 5099.80 1443.00 1.77 9.84 36.59
MyoKardia, Inc. MYOK 4325.84 34.00 12.57 -13.95 -201.73
Axsome Therapeutics, Inc. AXSM 2963.17 None 20.11 -32.94 None
Pacira Biosciences, Inc. PCRX 2275.14 435.00 6.10 -5417.00 -0.02
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
SAGE Therapeutics, Inc. SAGE 2181.92 9.00 2.56 -3.37 -413.06
Corcept Therapeutics, Inc. CORT 2023.98 335.00 4.65 19.07 31.64
Prestige Consumer Healthcare, Inc. PBH 1850.28 963.00 1.56 13.05 14.77
Revolution Medicines, Inc. RVMD 1738.14 48.00 4.51 -24.55 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1640.55 0.00 4.38 -16.06 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1595.90 440.00 -22.59 18.82 19.14
Innoviva, Inc. INVA 1580.87 285.00 3.74 8.18 66.41
Intercept Pharmaceuticals, Inc. ICPT 1475.20 272.00 -43.90 -4.30 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Zogenix, Inc. ZGNX 1313.55 5.00 3.59 -3.09 -241.62
Supernus Pharmaceuticals, Inc. SUPN 1274.94 402.00 2.02 10.93 28.90
Revance Therapeutics, Inc. RVNC 1230.46 0.00 4.86 -6.59 41.82
Theravance Biopharma, Inc. TBPH 1136.58 88.00 -7.98 -4.61 -280.80
Amphastar Pharmaceuticals, Inc. AMPH 1056.44 327.00 2.64 20.73 15.90
Endo International Plc ENDP 825.36 3014.00 -1.13 -2.94 -9.09
BellRing Brands, Inc. BRBR 771.22 954.00 -0.42 5.85 13.98
Assembly Biosciences, Inc. ASMB 693.39 16.00 3.11 -6.97 -601.75
Eagle Pharmaceuticals, Inc. EGRX 671.16 192.00 3.61 266.33 1.29
Aerie Pharmaceuticals, Inc. AERI 641.70 79.00 5.09 -3.17 -252.92
Collegium Pharmaceutical, Inc. COLL 593.64 299.00 4.25 -45.95 -4.21
Catalyst Pharmaceuticals, Inc. CPRX 537.14 119.00 5.23 12.24 36.09
Anika Therapeutics, Inc. ANIK 505.26 125.00 1.75 18.23 22.73
Intersect ENT, Inc. XENT 445.76 102.00 4.21 -8.93 -48.61
BioDelivery Sciences International, Inc. BDSI 401.12 130.00 5.74 -54.50 -5.01
ANI Pharmaceuticals, Inc. ANIP 376.08 203.00 1.92 -241.08 -0.67
Albireo Pharma, Inc. ALBO 332.41 11.00 3.38 -4.35 -730.55
MEI Pharma, Inc. MEIP 284.69 5.00 4.90 -7.30 -539.48
Mallinckrodt Plc MNK 209.16 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 163.43 None 2.66 -7.91 None
Marinus Pharmaceuticals, Inc. MRNS 161.60 0.00 6.26 -2.40 None
Cerecor, Inc. CERC 119.60 7.00 7.65 -5.31 -429.22
Ampio Pharmaceuticals, Inc. AMPE 95.81 1.00 67.00 -5.15 None
CTI BioPharma Corp. CTIC 91.45 3.00 4.08 -2.21 -111.83
Evoke Pharma, Inc. EVOK 89.28 None 31.00 -13.29 None
AcelRx Pharmaceuticals, Inc. ACRX 84.80 2.00 -1.56 -1.51 -644.25
Zynerba Pharmaceuticals, Inc. ZYNE 74.75 0.00 1.23 -2.08 -699.94
Adamas Pharmaceuticals, Inc. ADMS 71.68 57.00 -4.57 -0.77 -160.44
Aclaris Therapeutics, Inc. ACRS 68.88 4.00 1.21 -0.50 None
Oramed Pharmaceuticals, Inc. ORMP 60.30 3.00 4.86 -4.72 -464.15
Cassava Sciences, Inc. SAVA 59.28 41.00 3.12 -13.00 76.71
SCYNEXIS, Inc. SCYX 48.89 0.00 10.27 -1.26 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 48.60 47.00 0.99 -10.80 -9.59
Natural Alternatives International, Inc. NAII 47.11 114.00 0.65 -12.46 -3.19
Lipocine, Inc. LPCN 43.50 0.00 10.36 -2.90 None
IsoRay, Inc. ISR 42.88 9.00 8.00 -12.80 -36.08
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 35.45 65.00 -2.73 -2.03 -26.74
PLx Pharma, Inc. PLXP 27.00 0.00 -2.59 -2.86 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.24 3.00 2.39 -1.62 -264.21
Regulus Therapeutics, Inc. RGLS 18.15 0.00 1.60 -0.85 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.30 8.00 0.65 -0.15 -798.18
Intec Pharma Ltd. NTEC 10.66 None 1.37 -0.25 None
VIVUS, Inc. VVUS 8.88 73.00 -0.20 -0.30 -39.28
Sonoma Pharmaceuticals, Inc. SNOA 6.37 19.00 1.01 -2.04 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
Hepion Pharmaceuticals, Inc. HEPA 5.76 None 1.80 -0.48 None
Tonix Pharmaceuticals Holding Corp. TNXP 4.20 None 1.05 -0.09 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Drugmaker Vivus Files for Bankruptcy in Deal With IEH

10h ago, source: Wall Street Journal

Vivus, which has $235 million in funded debt, said it expects to emerge from bankruptcy with 62% less debt—about $90 ...

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

13h ago, source: YAHOO!

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH ...

BRIEF-Vivus files for Chapter 11 bankruptcy in Delaware -- court filing

10h ago, source: Reuters

July 7 (Reuters) - Vivus inc files for chapter 11 bankruptcy protection — court filing Vivus files for protection from creditors with u.s. Bankruptcy court in delaware Vivus says it had $213.9 mln ...

Pharma Co. Files Ch. 11 Plan Proposing Icahn Acquisition

8h ago, source: Law360

VIVUS Inc. and its subsidiaries voluntarily filed a prepackaged Chapter 11 reorganization plan in Delaware bankruptcy court Tuesday under which the California-based biopharmaceutical company would ...

VIVUS Inc.

6d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

16d ago, source: YAHOO!

Campbell, CA-based VIVUS, Inc. VVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs. The company's portfolio ...

BRIEF-Vivus Files For Offering Of Up To $185.5 Mln Of Common Shares Issuable Upon Exercise Of Warrants

29d ago, source: Reuters

June 9 (Reuters) - Vivus Inc: * VIVUS INC FILES FOR OFFERING OF OF UP TO $185.5 MILLION OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF WARRANTS Source text: (bit.ly/2XLf7T5) Further company ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.